

Long-term repeat OnabotulinumtoxinA provides durable symptom control and urodynamic protection without progressive loss of effect over time


BACKGROUND & METHODS

NDO requires lifelong management. Short-term trials confirm onabotulinumtoxinA efficacy, but durability of repeated injections and real world discontinuation patterns need clarification.

- **Design:** Systematic review (PRISMA/Cochrane).
- **Population:** Adults with NDO.
- **Intervention:** ≥ 3 injection cycles (200U or 300U).

CLINICAL EFFICACY

Robust, sustained reduction in daily urinary incontinence (UI) episodes across multiple reinjection cycles. No tachyphylaxis.



URODYNAMIC PROTECTION


Improvements maintained over long-term follow-up (up to 7 years) with no evidence of treatment-related fibrosis.



Clinical Implication: Monitor Voiding

Detrusor function **may not fully recover between cycles**. Crucial to **monitor pressure and PVR in spontaneously voiding patients** to detect impaired emptying. CIC patients are protected.

QUALITY OF LIFE (QOL)



DISCONTINUATION

3,7 – 42 % Overall rate. Mostly driven by non-clinical factors.

Primary Drivers of Cessation

- **True clinical failure is rare.**
Only 2% stopped due to non-response.
- **Disease progression (MS).**
Physical decline renders CIC impossible.
- **Logistical challenges.**
Personal reasons and loss to follow-up dominate.

Clinical Implication: Support

Structured pre-treatment education, peer support, and occupational therapy are vital to prepare patients for CIC and manage expectations regarding cyclical retreatment.

CONCLUSION

Repeated onabotulinumtoxinA provides a reliable, durable strategy for NDO without progressive loss of effect.

- Continence, urodynamics, & QoL gains persist.
- Discontinuation is largely modifiable (logistics/education) or due to disease progression, not drug failure.
- Cost-benefit vs. surgical alternatives requires discussion.

Clinical Implication: Manage Expectation

Clarify that symptom recurrence signifies the need for the next dose, **not therapeutic failure**.



Long-term Efficacy and Discontinuation Rates of Repeat OnabotulinumtoxinA Injections for Neurogenic Detrusor Overactivity: A Systematic Review

Saras Serani Sesari^{a,b}, Marvel Pratama Tjiaman^c

^aDepartment of Urology, Faculty of Medicine, Universitas Indonesia, Jakarta

^bDepartment of Urology, Rumah Sakit Universitas Indonesia, Depok, West Java

^cFaculty of Medicine, Universitas Indonesia, Jakarta

www.ics.org/2026/abstract/776




CLINICAL EFFICACY

Robust, sustained reduction in daily urinary incontinence (UI) episodes across multiple reinjection cycles. No tachyphylaxis.

4.8

4.8




Baseline

>83%

Patients with $\geq 50\%$ UI reduction

1.8



6 Years

9-11

Months stable duration